HIV
Dermatology, Venereology & Leprosy · Topic 11
Source: NMC CBME Curriculum 2024 · Volume II · Dermatology, Venereology & Leprosy · Topic 11 · combined PDF page 359
Practice questions
- In a systematic review of mpox patients, what was the pooled relative risk of hospitalization associated with HIV coinfection?
- The pooled meta-analytic estimate for mortality in mpox patients with HIV compared with those without HIV was closest to which value?
- A clinician reviewing mpox in a person with HIV notes perianal lesions. How does this finding compare with the pooled pattern reported in patients with HIV versus those without HIV?
- Which anorectal symptom pattern was reported more frequently among mpox patients with HIV in the meta-analysis?
- Which pair of complications was reported more frequently in mpox patients with HIV than in those without HIV?
- A pooled analysis found more syphilis, HBV, and HCV coinfections among mpox patients with HIV. Which interpretation is most appropriate?
- The mpox meta-analysis reported higher fever, malaise, and diarrhoea among patients with HIV. Which conclusion is best supported?
- Exploratory subgroup analyses of mpox outcomes suggested that which factor may contribute to poorer outcomes among people with HIV?
- A reader concludes from the mpox review that poor viral suppression definitively causes severe lesions. What is the most important limitation to note?
- In the systematic review of prophylactic HPV vaccines in people with HIV, what was the pooled seroconversion estimate for HPV16?
- Which comparison best reflects the reported influence of CD4 count on HPV16 seroconversion in people with HIV?
- A person with HIV has a CD4 count of 150 cells/μL and is being counselled about prophylactic HPV vaccination. Which statement is supported by the meta-analysis?
- Which statement about safety was reported in the systematic review of prophylactic HPV vaccines in people with HIV?
- In which population did the review report that two doses of nonavalent HPV vaccine were non-inferior to three doses?
- The review reported pooled seroconversion estimates of 97.8% for HPV16 and 94.2% for HPV18. How did the review grade the certainty of evidence for these two types?
- Which conclusion best reflects the overall findings on prophylactic HPV vaccine immunogenicity across vaccine generations in people with HIV?